[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1112229T1 - Αντισωματα κατευθυνομενα εναντι οξειδωμενης απολιποπρωτεϊνης β - Google Patents

Αντισωματα κατευθυνομενα εναντι οξειδωμενης απολιποπρωτεϊνης β

Info

Publication number
CY1112229T1
CY1112229T1 CY20111100305T CY111100305T CY1112229T1 CY 1112229 T1 CY1112229 T1 CY 1112229T1 CY 20111100305 T CY20111100305 T CY 20111100305T CY 111100305 T CY111100305 T CY 111100305T CY 1112229 T1 CY1112229 T1 CY 1112229T1
Authority
CY
Cyprus
Prior art keywords
oxidated
protein
self
guided against
passive immunization
Prior art date
Application number
CY20111100305T
Other languages
English (en)
Inventor
Jan Nilsson
Roland Carlsson
Jenny Bengtsson
Leif Strandberg
Original Assignee
Bioinvent International Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0202959A external-priority patent/SE0202959D0/xx
Application filed by Bioinvent International Ab filed Critical Bioinvent International Ab
Publication of CY1112229T1 publication Critical patent/CY1112229T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση αφορά παθητική ανοσοποίηση για θεραπεία ή αποτροπή αθηροσκλήρωσης χρησιμοποιώντας ανασυνδυασμένο ανθρώπινο αντίσωμα κατευθυνόμενο έναντι τουλάχιστον ενός οξειδωμένου θραύσματος απολιποπρωτεΐνης Β στην βιομηχανική κατασκευή μιας φαρμακευτικής σύνθεσης για θεραπευτική ή προφυλακτική αγωγή αθηροσκλήρωσης με την βοήθεια παθητικής ανοσοποίησης, καθώς επίσης μέθοδο για παρασκευή τέτοιων αντισωμάτων και μέθοδο για την θεραπεία θηλαστικού, κατά προτίμηση ανθρώπου, χρησιμοποιώντας ένα τέτοιο αντίσωμα για να παρέχεται παθητική ανοσοποίηση.
CY20111100305T 2002-10-04 2011-03-21 Αντισωματα κατευθυνομενα εναντι οξειδωμενης απολιποπρωτεϊνης β CY1112229T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0202959A SE0202959D0 (sv) 2002-10-04 2002-10-04 Peptide-Base passive immunization therapy for treatment of atherosclerosis
SE0302312A SE0302312D0 (sv) 2002-10-04 2003-08-27 Peptide-based passive immunization therapy for treatment of atherosclerosis
EP03748843A EP1545609B1 (en) 2002-10-04 2003-10-06 Antibodies directed against oxidised apolipoprotein B

Publications (1)

Publication Number Publication Date
CY1112229T1 true CY1112229T1 (el) 2015-12-09

Family

ID=28677712

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100305T CY1112229T1 (el) 2002-10-04 2011-03-21 Αντισωματα κατευθυνομενα εναντι οξειδωμενης απολιποπρωτεϊνης β

Country Status (20)

Country Link
US (6) US7468183B2 (el)
EP (3) EP2359848A1 (el)
JP (5) JP2006506450A (el)
CN (3) CN102319429A (el)
AT (1) ATE498407T1 (el)
AU (2) AU2003263712A1 (el)
BR (1) BR0315042A (el)
CY (1) CY1112229T1 (el)
DE (1) DE60336068D1 (el)
DK (1) DK1545609T3 (el)
EE (1) EE200500012A (el)
ES (1) ES2387423T3 (el)
HK (1) HK1087018A1 (el)
PL (1) PL376964A1 (el)
PT (1) PT1545609E (el)
RU (2) RU2322260C2 (el)
SE (1) SE0302312D0 (el)
SI (1) SI1545609T1 (el)
TW (2) TW200835517A (el)
WO (1) WO2004030698A1 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1531162A1 (en) * 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
GB0517878D0 (en) * 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
AU2008342942A1 (en) * 2007-12-28 2009-07-09 Biolnvent International Ab Formulation
BRPI0914091B1 (pt) 2008-10-14 2022-05-10 Genentech Inc Igg variante, composição farmacêutica, kit e usos de um igg variante
JP2012517216A (ja) * 2009-02-09 2012-08-02 パトリス リミテッド Ｓａｍ−６変異体、標的および使用法
CN102439035A (zh) 2009-03-17 2012-05-02 佛斯卡专利公司 治疗和/或预防动脉粥样硬化的免疫调节方法和系统，以及相关蛋白、肽和组合物
CU23736A1 (es) 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
CA2772380A1 (en) * 2009-08-28 2011-03-03 Genentech, Inc. Methods of treatment using anti-oxidized ldl antibodies
CN102939536A (zh) 2009-11-14 2013-02-20 匡-宇·邱 用于治疗和/或预防动脉粥样硬化的免疫调节方法和系统
CA2817543A1 (en) 2010-11-12 2012-06-07 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
WO2012065133A1 (en) 2010-11-12 2012-05-18 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of aneurysms
CA2877127A1 (en) * 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Analogs of glucagon exhibiting gip receptor activity
EP3463416A1 (en) 2016-05-31 2019-04-10 CardioVax, LLC Methods for diagnosing and treating systemic lupus erythematosus
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
CN110950952A (zh) * 2019-12-17 2020-04-03 东莞市东阳光生物药研发有限公司 制备抗体的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970144A (en) * 1984-12-31 1990-11-13 International Genetic Engineering Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5972890A (en) * 1988-05-02 1999-10-26 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
US5196324A (en) * 1989-12-15 1993-03-23 Eli Lilly And Company Monoclonal antibodies reactive with a human atheroma associated antigen
WO1994000592A1 (en) * 1992-06-26 1994-01-06 Exocell, Inc. Monoclonal antibodies against glycated low density lipoprotein
US5678548A (en) 1995-07-20 1997-10-21 The United States Of America As Represented By The Department Of Health And Human Services System and method for performing in vivo imaging and oxymetry and FT microscopy by pulsed radiofrequency electron paramagnetic resonance
CN1206421A (zh) * 1995-11-01 1999-01-27 科斯药品公司 载脂蛋白e2和阿尔采默氏病的治疗
KR0185334B1 (ko) * 1995-11-02 1999-04-01 김은영 인간 혈장 아포지단백질 비-100에 결합하는 생쥐 항체를 암호하는 씨디엔에이
GB9620153D0 (en) 1996-09-27 1996-11-13 Univ Strathclyde Non-naturally occurring lipoprotein particle
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
GB9705831D0 (en) * 1997-03-20 1997-05-07 Univ Leicester Oxidised ldl
US6635623B1 (en) 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
US6225070B1 (en) 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
BR9811163A (pt) * 1997-08-12 2000-07-25 Leadd Bv Processos para determinar a capacidade de transformação de um possìvel agente transformador, a predisposição de uma célula em tornar-se uma célula de tumor e de um indivìduo a tipos hereditários de câncer, e uma mutação de gene apresentando atividade oncogênica e/ou transformadora em uma célula, uso de um ácido nucleico codificando apoptina ou um seu fragmento ou derivado funcional, e, kit de teste diagnóstico
US6156315A (en) 1997-10-10 2000-12-05 The Trustees Of Columbia University In The City Of New York Method for inhibiting the binding of low density lipoprotein to blood vessel matrix
AU5200699A (en) 1998-07-13 2000-02-01 University Of Otago Inhibition of lipoprotein formation
CA2389849A1 (en) * 1999-10-26 2001-05-10 Regents Of The University Of California Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
CN1418106A (zh) * 2000-03-03 2003-05-14 史密丝克莱恩比彻姆生物有限公司 疫苗
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US20030105003A1 (en) * 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
JP4159300B2 (ja) 2001-07-05 2008-10-01 株式会社リコー 画像定着装置及び画像形成装置

Also Published As

Publication number Publication date
ES2387423T3 (es) 2012-09-21
ATE498407T1 (de) 2011-03-15
US8114966B2 (en) 2012-02-14
JP2010104374A (ja) 2010-05-13
SE0302312D0 (sv) 2003-08-27
BR0315042A (pt) 2005-08-23
EP1545609A2 (en) 2005-06-29
WO2004030698A1 (en) 2004-04-15
PT1545609E (pt) 2011-05-11
US20070098723A1 (en) 2007-05-03
SI1545609T1 (sl) 2011-05-31
US7521046B2 (en) 2009-04-21
US7468183B2 (en) 2008-12-23
US20090155258A1 (en) 2009-06-18
JP2006506450A (ja) 2006-02-23
JP2010136721A (ja) 2010-06-24
EP1545609B1 (en) 2011-02-16
HK1087018A1 (en) 2006-10-06
AU2009201260B2 (en) 2011-07-28
DK1545609T3 (da) 2011-05-02
US20120070426A1 (en) 2012-03-22
TWI299666B (en) 2008-08-11
TW200835517A (en) 2008-09-01
RU2322260C2 (ru) 2008-04-20
AU2003263712A1 (en) 2004-04-23
TW200418504A (en) 2004-10-01
CN102172400A (zh) 2011-09-07
AU2009201260A1 (en) 2009-04-23
JP2010104375A (ja) 2010-05-13
DE60336068D1 (de) 2011-03-31
EE200500012A (et) 2005-08-15
RU2005113235A (ru) 2006-01-20
EP2359848A1 (en) 2011-08-24
PL376964A1 (pl) 2006-01-09
JP2010222378A (ja) 2010-10-07
EP2361633A1 (en) 2011-08-31
US20080075716A1 (en) 2008-03-27
US20040202653A1 (en) 2004-10-14
RU2007140978A (ru) 2009-05-10
US20080008702A1 (en) 2008-01-10
CN102380097A (zh) 2012-03-21
US7601353B2 (en) 2009-10-13
CN102319429A (zh) 2012-01-18

Similar Documents

Publication Publication Date Title
CY1112229T1 (el) Αντισωματα κατευθυνομενα εναντι οξειδωμενης απολιποπρωτεϊνης β
DK1385864T3 (da) Anti-VEGF-2-antistoffer
ATE415423T1 (de) Immunisierungstherapie zur behandlung von atherosklerose
CY1109525T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2
BR0315161A (pt) Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição
LU93274I2 (fr) Elotuzumab
NI200600098A (es) Anticuerpos que se unen al receptor de interleuquina-4
DK0758904T3 (da) Fremgangsmåder og sammensætninger til behandling af glomerulonephritis
ATE402192T1 (de) Anti-ccr4 antikörper und fragmente davon
ATE423571T1 (de) Verwendung von bispezifischen antikörpern gegen einen aktivierenden rezeptor fcepsilonri und gegen einen inhibierenden rezeptor ox2ra (cd200ra) zur regulierung der immunantworten
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
ATE361100T1 (de) Methode zur krebs-behandlung mit anti- neurotrophin mittel
ATE373719T1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
DE60320009D1 (de) Transplant-Akzeptanz induzierende Zellen monocytären ursprungs, sowie deren Herstellung und Verwendung
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
ATE525480T1 (de) Verwendung von a33-antigenen und jam-it
WO2004030607A3 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
ATE348161T1 (de) Fctrx genannte proteine und dafür kodierende nuklein säure
ATE435028T1 (de) Impfstoff gegen neisseria infektion
SE0202959D0 (sv) Peptide-Base passive immunization therapy for treatment of atherosclerosis
WO2007012671A3 (fr) Procédé d'immunisation génétique par électrotransfert contre une toxine et antisérum susceptible d'être obtenu par ledit procédé